Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
- PMID: 28275683
- PMCID: PMC5331831
- DOI: 10.1016/j.jcmgh.2017.01.006
Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
Abstract
In patients with colorectal cancer (CRC) that metastasizes to the liver, there are several key goals for improving outcomes including early detection, effective prognostic indicators of treatment response, and accurate identification of patients at high risk for recurrence. Although new therapeutic regimens developed over the past decade have increased survival, there is substantial room for improvement in selecting targeted treatment regimens for the patients who will derive the most benefit. Recently, there have been exciting developments in identifying high-risk patient cohorts, refinements in the understanding of systemic vs localized drug delivery to metastatic niches, liquid biomarker development, and dramatic advances in tumor immune therapy, all of which promise new and innovative approaches to tackling the problem of detecting and treating the metastatic spread of CRC to the liver. Our multidisciplinary group held a state-of-the-science symposium this past year to review advances in this rapidly evolving field. Herein, we present a discussion around the issues facing treatment of patients with CRC liver metastases, including the relationship of discrete gene signatures with prognosis. We also discuss the latest advances to maximize regional and systemic therapies aimed at decreasing intrahepatic recurrence, review recent insights into the tumor microenvironment, and summarize advances in noninvasive multimodal biomarkers for early detection of primary and recurrent disease. As we continue to advance clinically and technologically in the field of colorectal tumor biology, our goal should be continued refinement of predictive and prognostic studies to decrease recurrence after curative resection and minimize treatment toxicity to patients through a tailored multidisciplinary approach to cancer care.
Keywords: 5-FU, fluorouracil; Biomarkers; CDX2, caudal-type homeobox transcription factor 2; CEA, carcinoembryonic antigen; CK, cytokeratin; CRC, colorectal cancer; CRLM, colorectal cancer liver metastasis; CTC, circulating tumor cells; Colorectal Cancer Liver Metastasis; DFS, disease-free survival; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; HAI, hepatic arterial infusion; Hepatic Arterial Infusion; High-Risk Colorectal Cancer; IL, interleukin; LV, leucovorin; MSI, microsatellite instability; OS, overall survival; PD, programmed death; Recurrence; TH, T-helper; cfDNA, cell-free DNA; dMMR, deficient mismatch repair; miRNA, microRNA.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5331831/bin/gr1.gif)
Similar articles
-
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).BMC Cancer. 2018 Aug 6;18(1):787. doi: 10.1186/s12885-018-4697-7. BMC Cancer. 2018. PMID: 30081865 Free PMC article.
-
Updated Management of Colorectal Cancer Liver Metastases: Scientific Advances Driving Modern Therapeutic Innovations.Cell Mol Gastroenterol Hepatol. 2023;16(6):881-894. doi: 10.1016/j.jcmgh.2023.08.012. Epub 2023 Sep 9. Cell Mol Gastroenterol Hepatol. 2023. PMID: 37678799 Free PMC article. Review.
-
Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.Gan To Kagaku Ryoho. 1999 Feb;26(3):269-81. Gan To Kagaku Ryoho. 1999. PMID: 10065089 Review.
-
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.Arch Pathol Lab Med. 2018 Jan;142(1):17-25. doi: 10.5858/arpa.2017-0040-RA. Epub 2017 Nov 16. Arch Pathol Lab Med. 2018. PMID: 29144791 Review.
-
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.Surg Oncol. 2018 Jun;27(2):280-288. doi: 10.1016/j.suronc.2018.05.012. Epub 2018 May 8. Surg Oncol. 2018. PMID: 29937183 Review.
Cited by
-
An evaluation model of hepatic steatosis based on CT value and serum uric acid/HDL cholesterol ratio can predict intrahepatic recurrence of colorectal cancer liver metastasis.Int J Clin Oncol. 2024 Jun 5. doi: 10.1007/s10147-024-02550-y. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38839664
-
Hypoxia-inducible factor 3α1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis.Br J Cancer. 2024 Jun;130(12):1904-1915. doi: 10.1038/s41416-024-02699-3. Epub 2024 May 1. Br J Cancer. 2024. PMID: 38693428
-
SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis.J Exp Clin Cancer Res. 2024 Apr 26;43(1):126. doi: 10.1186/s13046-024-03053-4. J Exp Clin Cancer Res. 2024. PMID: 38671459 Free PMC article.
-
Multi-omics data-based analysis characterizes molecular alterations of the vesicle genes in human colorectal cancer.Am J Cancer Res. 2024 Mar 15;14(3):1402-1418. doi: 10.62347/QFKD1805. eCollection 2024. Am J Cancer Res. 2024. PMID: 38590397 Free PMC article.
-
Identification and analysis of prognostic metabolic characteristics in colon adenocarcinoma.Heliyon. 2024 Mar 5;10(6):e27388. doi: 10.1016/j.heliyon.2024.e27388. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38509965 Free PMC article.
References
-
- Ferlay J., Soerjomataram I., Dikshit R. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
-
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J Clin. 2016;2016(66):7–30. - PubMed
-
- Tomlinson J.S., Jarnagin W.R., DeMatteo R.P. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575–4580. - PubMed
-
- House M.G., Kemeny N.E., Gönen M. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011;254:851–856. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous